Promoter holding
64.27%
RL
Rpg Life Sciences Limited - Due diligence report
A 360° intelligence report on Rpg Life Sciences: trust score, financial health, credit view, compliance, directors, growth and distress sign…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹349
50% off
New user
Or enjoy up to 50% off with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Rpg Life Sciences — 360° Intelligence Report
Generated from MCA filings & public records81/100
Trust Score
Low Risk
Rpg Life Sciences is assessed as Low Risk with a Trust Score of 81/100. Rpg Life Sciences is an active public limited indian non-government company incorporated in 2007, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.
Report generated on 21 Jun 2026 from the latest processed filings. Rpg Life Sciences Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
81/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
78/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
90/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
90/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreCaution Indicated
45/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
90/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 90/100 Low Risk
- Liabilities ≈ 38% EBITDA - serviceable.
- Working-capital cover adequate.
- Profitable - internal accruals available.
- Externally credit-rated (A).
Charges position: 1 open (65.92 cr) · 9 satisfied (71.07 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Others | 2 | 48.0 cr |
| Export-Import Bank Of India | 4 | 48.0 cr |
| Export Import Bank Of India | 2 | 48.0 cr |
| Union Bank Of India | 2 | 48.0 cr |
Compliance Score: 78/100 Low Risk
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Litigation present in 2 court forum(s).
- Delayed payments to MSME suppliers disclosed (24 disclosure(s)).
- 17 active GST registration(s).
Legal cases on record (2)
05
Director Intelligence
Stability score: 45/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| SACHIN RAJKUMAR NANDGAONKAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VASUNDHARA APOORVA PATNI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VISHAL DILIP SHAH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAJESH RAMESH SHIRAMBEKAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| HITEN KANTILAL KOTAK | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ANILKUMAR MATAI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAJAT BHARGAVA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAJESH RAMESH SHIRAMBEKAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ASHOK NAIR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MANOJKUMAR MADANGOPAL MAHESHWARI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| YUGAL KISHOR CHOTHURAM SIKRI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RADHIKA GUPTA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| HARSH VARDHAN GOENKA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ZAHABIYA HABIL KHORAKIWALA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| BHASKAR VEMBAN IYER | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Amol Narayan Lone | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 16 directors on the board.
- HITEN KANTILAL KOTAK has DIN status "Deactivated due to non-filing of DIR-3 KYC".
- 2 director exit(s) in the last 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2023 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
5 allotment(s) · 1 transfer(s)
Promoters hold a majority stake - exact percentages are part of the full report.
Key managerial personnel: VISHAL DILIP SHAH (CFO) · ASHOK NAIR (Managing Director) · Amol Narayan Lone (CFO)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 90 · Distress 90
Growth signals & trust indicators
Revenue acceleration: +1.42 over 4 year(s).
Profit expanded 2.1x year-on-year.
Asset base grew 24% - capacity expansion.
Net margin improved to 0.86.
Operating for 19+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
1 open charge(s) registered - assets are encumbered.
MSME payment delays disclosed - latest outstanding 9.88 Lakh.
2 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence82/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- No distress signals on file.
- Financial filings available for verification.
Banker assessment87/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 1 open charge(s) of 65.92 cr already registered.
- Compliance record supports lending.
Investor view88/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 4 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management churn warrants questions.
09
MCA Filings & Events Timeline
Latest 15 events15 Dec 2025
Director appointed
Amol Narayan Lone (CFO)
16 Jul 2025
Last AGM held
Annual general meeting
15 Jul 2025
Director ceased
VASUNDHARA APOORVA PATNI
Director ceased
ASHOK NAIR
01 May 2025
Director appointed
ASHOK NAIR (Managing Director)
Director appointed
YUGAL KISHOR CHOTHURAM SIKRI (Director)
28 Apr 2025
Director appointed
VASUNDHARA APOORVA PATNI (Director)
31 Mar 2025
Latest balance sheet
Filed with ROC
30 Apr 2024
Director appointed
HITEN KANTILAL KOTAK (Additional Director)
Director appointed
ANILKUMAR MATAI (Additional Director)
Director appointed
RADHIKA GUPTA (Additional Director)
31 Aug 2021
Director ceased
RAJAT BHARGAVA
25 Jan 2021
Director appointed
RAJAT BHARGAVA (Director)
09 Oct 2020
Charge satisfied
Others
20 Aug 2020
Director ceased
SACHIN RAJKUMAR NANDGAONKAR
10
Key Observations
Auto-generated from the data aboveRevenue grew 61% over the last 4 financial year(s).
Net profit margin moved from 38% to 1.42.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
16 active director(s) / partner(s); review board churn before relying on management continuity.
17 active GST registration(s) indicate ongoing business operations.
Carries an external credit rating of A from Icra.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a majority stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 5 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Bhageria Group Of Companies | L40300MH1989PLC052574 | Mumbai, Maharashtra, India |
| Diach Chemicals & Pigments Private Limited | U24299WB2004PTC099689 | Howrah, West Bengal, India |
| Anthea Aromatics | U24100MH2008PTC179684 | Navi Mumbai, Maharashtra, India |
| Navin Fluorine Advanced Sciences Limited | U24297MH2020PLC337262 | Mumbai, Maharashtra, India |
| Universal Starch-Chem Allied | L24110MH1973PLC016247 | Mumbai, Maharashtra, India |
| Penam Laboratories | U24231DL1989PLC037287 | New Delhi, Delhi, India |
| Gramercy Trade Industries Private Limited | U24112PN2021PTC205986 | Pune, Maharashtra, India |
| Aculife Healthcare | U24233GJ2014PTC080271 | Ahmedabad, Gujarat, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Rpg Life Sciences before audits and certifications: compliance score 78/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Rpg Life Sciences: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 90/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 90/100, margin trends, ownership structure and peer set for Rpg Life Sciences - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 81/100, distress signals and MSME payment-delay disclosures - know whether Rpg Life Sciences pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Rpg Life Sciences - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Rpg Life Sciences an active company?
Rpg Life Sciences has MCA status “Active” with a compliance score of 78/100 (Low Risk).
Is Rpg Life Sciences financially healthy?
Rpg Life Sciences has a Financial Health Score of 90/100 (Low Risk) based on its filed financial statements.
Should I do business with Rpg Life Sciences?
Its overall Trust Score is 81/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Rpg Life Sciences?
Promoters hold a majority stake - exact percentages are in the full report. 16 active director(s) are on record.
Does Rpg Life Sciences have loans or charges against its assets?
1 open charge(s) are registered against its assets, and 9 earlier charge(s) stand satisfied.
Is Rpg Life Sciences up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 78/100 (Low Risk).
Is it risky to lend to Rpg Life Sciences?
Its Credit Risk Score is 90/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
